These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 11895127

  • 21. Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
    Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E.
    J Mol Neurosci; 2002; 19(1-2):63-9. PubMed ID: 12212795
    [Abstract] [Full Text] [Related]

  • 22. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
    Culvenor JG, McLean CA, Cutt S, Campbell BC, Maher F, Jäkälä P, Hartmann T, Beyreuther K, Masters CL, Li QX.
    Am J Pathol; 1999 Oct; 155(4):1173-81. PubMed ID: 10514400
    [Abstract] [Full Text] [Related]

  • 23. A review on the cause-effect relationship between oxidative stress and toxic proteins in the pathogenesis of neurodegenerative diseases.
    Borza LR.
    Rev Med Chir Soc Med Nat Iasi; 2014 Oct; 118(1):19-27. PubMed ID: 24741770
    [Abstract] [Full Text] [Related]

  • 24. Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?
    Kurosinski P, Guggisberg M, Götz J.
    Trends Mol Med; 2002 Jan; 8(1):3-5. PubMed ID: 11796255
    [Abstract] [Full Text] [Related]

  • 25. Involvement of alpha-synuclein in Parkinson's disease and other neurodegenerative disorders.
    Krüger R, Müller T, Riess O.
    J Neural Transm (Vienna); 2000 Jan; 107(1):31-40. PubMed ID: 10809401
    [Abstract] [Full Text] [Related]

  • 26. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
    Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, Marsh L, Troncoso JC.
    Neurobiol Aging; 2005 Jan; 26(8):1183-92. PubMed ID: 15917102
    [Abstract] [Full Text] [Related]

  • 27. The synuclein family.
    Lavedan C.
    Genome Res; 1998 Sep; 8(9):871-80. PubMed ID: 9750188
    [Abstract] [Full Text] [Related]

  • 28. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease.
    Savelieff MG, DeToma AS, Derrick JS, Lim MH.
    Acc Chem Res; 2014 Aug 19; 47(8):2475-82. PubMed ID: 25080056
    [Abstract] [Full Text] [Related]

  • 29. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
    Goedert M.
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun 29; 354(1386):1101-18. PubMed ID: 10434313
    [Abstract] [Full Text] [Related]

  • 30. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders.
    Takeda A, Mallory M, Sundsmo M, Honer W, Hansen L, Masliah E.
    Am J Pathol; 1998 Feb 29; 152(2):367-72. PubMed ID: 9466562
    [Abstract] [Full Text] [Related]

  • 31. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
    El-Agnaf OM, Irvine GB.
    J Struct Biol; 2000 Jun 29; 130(2-3):300-9. PubMed ID: 10940234
    [Abstract] [Full Text] [Related]

  • 32. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease.
    Uversky VN, Li J, Bower K, Fink AL.
    Neurotoxicology; 2002 Oct 29; 23(4-5):527-36. PubMed ID: 12428725
    [Abstract] [Full Text] [Related]

  • 33. The amyloid state of proteins: A boon or bane?
    Hassan MN, Nabi F, Khan AN, Hussain M, Siddiqui WA, Uversky VN, Khan RH.
    Int J Biol Macromol; 2022 Mar 01; 200():593-617. PubMed ID: 35074333
    [Abstract] [Full Text] [Related]

  • 34. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA.
    Acta Neuropathol; 2003 Sep 01; 106(3):191-201. PubMed ID: 12845452
    [Abstract] [Full Text] [Related]

  • 35. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders.
    Uversky VN.
    J Biomol Struct Dyn; 2003 Oct 01; 21(2):211-34. PubMed ID: 12956606
    [Abstract] [Full Text] [Related]

  • 36. Challenges and complexities of alpha-synuclein toxicity: new postulates in unfolding the mystery associated with Parkinson's disease.
    Hegde ML, Jagannatha Rao KS.
    Arch Biochem Biophys; 2003 Oct 15; 418(2):169-78. PubMed ID: 14522588
    [Abstract] [Full Text] [Related]

  • 37. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G, Schlüter OM, Südhof TC.
    Nat Neurosci; 2008 Mar 15; 11(3):301-8. PubMed ID: 18297066
    [Abstract] [Full Text] [Related]

  • 38. Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease.
    Allsop D, Mayes J, Moore S, Masad A, Tabner BJ.
    Biochem Soc Trans; 2008 Dec 15; 36(Pt 6):1293-8. PubMed ID: 19021543
    [Abstract] [Full Text] [Related]

  • 39. Neuropathology of synuclein aggregates.
    Duda JE, Lee VM, Trojanowski JQ.
    J Neurosci Res; 2000 Jul 15; 61(2):121-7. PubMed ID: 10878583
    [Abstract] [Full Text] [Related]

  • 40. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
    Bourdenx M, Koulakiotis NS, Sanoudou D, Bezard E, Dehay B, Tsarbopoulos A.
    Prog Neurobiol; 2017 Aug 15; 155():171-193. PubMed ID: 26209472
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.